NCT07165678 CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)
| NCT ID | NCT07165678 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Coronary Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-04-16 |
| Primary Completion | 2029-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2026-04-16 with a primary completion date of 2029-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina or myocardial infarction following coronary artery bypass graft (CABG) surgery. The main questions it aims to answer are: * Can CTCA reduce major adverse cardiovascular events compared to standard invasive coronary angiography? * Is CTCA a cost-effective and safer alternative that improves patient quality of life? Researchers will compare outcomes between patients receiving CTCA prior to angiography and those undergoing standard angiography alone to determine if CTCA improves clinical outcomes and procedural safety. Participants will: * Be randomly assigned to either CTCA-guided care or standard angiography * Undergo coronary imaging and follow-up assessments * Complete questionnaires on quality of life and healthcare resource use
Eligibility Criteria
Inclusion Criteria: * Aged ≥18 * Previous coronary artery bypass grafting (CABG) * An indication for coronary angiography * Angina * Ischaemia on perfusion imaging * Acute coronary syndrome * Patients are able and willing to give their written informed consent Exclusion Criteria: * Subjects presenting with ST segment myocardial infarction within window for primary PCI * Patients considered unsuitable to participate by the research team (e.g. due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures) * Life expectancy less than 1 year
Contact & Investigator
Daniel Jones, MRCP, PhD
PRINCIPAL INVESTIGATOR
Queen Mary University of London
Frequently Asked Questions
Who can join the NCT07165678 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Coronary Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07165678 currently recruiting?
Yes, NCT07165678 is actively recruiting participants. Contact the research team at mervyn.andiapen@nhs.net for enrollment information.
Where is the NCT07165678 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT07165678 clinical trial?
NCT07165678 is sponsored by Queen Mary University of London. The principal investigator is Daniel Jones, MRCP, PhD at Queen Mary University of London. The trial plans to enroll 1,000 participants.